These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 19081511

  • 21. Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient.
    Tortorella C, Direnzo V, D'Onghia M, Trojano M.
    Neurology; 2013 Oct 15; 81(16):1470-1. PubMed ID: 24127190
    [No Abstract] [Full Text] [Related]

  • 22. Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab.
    Langer-Gould A, Steinman L.
    Curr Neurol Neurosci Rep; 2006 May 15; 6(3):253-8. PubMed ID: 16635435
    [Abstract] [Full Text] [Related]

  • 23. Natalizumab for relapsing multiple sclerosis.
    Meyer MA.
    N Engl J Med; 2006 Jun 01; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742009
    [No Abstract] [Full Text] [Related]

  • 24. Natalizumab and progressive multifocal leukoencephalopathy.
    Adelman B, Sandrock A, Panzara MA.
    N Engl J Med; 2005 Jul 28; 353(4):432-3. PubMed ID: 15947083
    [No Abstract] [Full Text] [Related]

  • 25. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.
    Putzki N, Kollia K, Woods S, Igwe E, Diener HC, Limmroth V.
    Eur J Neurol; 2009 Mar 28; 16(3):424-6. PubMed ID: 19187261
    [Abstract] [Full Text] [Related]

  • 26. Unusual natalizumab-associated progressive multifocal leukoencephalopathy starting in the brainstem.
    Havla J, Hohlfeld R, Kümpfel T.
    J Neurol; 2014 Jan 28; 261(1):232-4. PubMed ID: 24276521
    [No Abstract] [Full Text] [Related]

  • 27. [New drugs; natalizumab].
    van Bronswijk H, Dubois EA, van Gerven JM, Cohen AF.
    Ned Tijdschr Geneeskd; 2008 Mar 01; 152(9):499-500. PubMed ID: 18389881
    [Abstract] [Full Text] [Related]

  • 28. Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance.
    Blair NF, Brew BJ, Halpern JP.
    Neurology; 2012 Feb 14; 78(7):507-8. PubMed ID: 22302545
    [No Abstract] [Full Text] [Related]

  • 29. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
    Johnson KP.
    Neurologist; 2007 Jul 14; 13(4):182-7. PubMed ID: 17622909
    [Abstract] [Full Text] [Related]

  • 30. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
    Damasceno A, von Glehn F, Martinez AR, Longhini AL, Deus-Silva L, Brandão CO, Santos LM, Damasceno BP.
    Mult Scler; 2011 Nov 14; 17(11):1397-8. PubMed ID: 21900356
    [No Abstract] [Full Text] [Related]

  • 31. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 32. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.
    Dorsey ER, Thompson JP, Noyes K, Dick AW, Holloway RG, Schwid SR.
    Neurology; 2007 May 01; 68(18):1524-8. PubMed ID: 17470756
    [Abstract] [Full Text] [Related]

  • 33. Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.
    Berger JR, Koralnik IJ.
    N Engl J Med; 2005 Jul 28; 353(4):414-6. PubMed ID: 15947082
    [No Abstract] [Full Text] [Related]

  • 34. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
    Martin Mdel P, Cravens PD, Winger R, Kieseier BC, Cepok S, Eagar TN, Zamvil SS, Weber MS, Frohman EM, Kleinschmidt-Demasters BK, Montine TJ, Hemmer B, Marra CM, Stüve O.
    Arch Neurol; 2009 Aug 28; 66(8):1016-20. PubMed ID: 19667224
    [Abstract] [Full Text] [Related]

  • 35. Interruption of natalizumab therapy for multiple sclerosis: what are the risks?
    Naismith RT, Bourdette D.
    Neurology; 2011 May 31; 76(22):1854-5. PubMed ID: 21543735
    [No Abstract] [Full Text] [Related]

  • 36. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy.
    Vermersch P, Kappos L, Gold R, Foley JF, Olsson T, Cadavid D, Bozic C, Richman S.
    Neurology; 2011 May 17; 76(20):1697-704. PubMed ID: 21576685
    [Abstract] [Full Text] [Related]

  • 37. Rituximab in relapsing-remitting multiple sclerosis.
    Schrijver HM.
    N Engl J Med; 2008 Jun 12; 358(24):2645; author reply 2646-7. PubMed ID: 18557177
    [No Abstract] [Full Text] [Related]

  • 38. Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate.
    Yildiz M, Tettenborn B, Putzki N.
    Eur Neurol; 2011 Jun 12; 65(4):231-2. PubMed ID: 21454981
    [No Abstract] [Full Text] [Related]

  • 39. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
    Peaureaux D, Pignolet B, Biotti D, Bucciarelli F, Gaina J, Bucur C, Clanet M, Martin-Blondel G, Brassat D.
    Mult Scler; 2015 Apr 12; 21(5):671-2. PubMed ID: 25305251
    [No Abstract] [Full Text] [Related]

  • 40. Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab.
    Baumgartner A, Stich O, Rauer S.
    Int J Neurosci; 2012 Jan 12; 122(1):35-9. PubMed ID: 21913869
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.